Novartis to Pay $422.5M to Settle Off-label Drug Marketing Charges

Novartis Pharmaceuticals Corp. will plead guilty and pay criminal and civil fines totaling $422.5 million to resolve claims that it used off-label marketing to illegally promote the antiepileptic Trileptal and five other drugs, federal prosecutors said Thursday.

1 comments on "Novartis to Pay $422.5M to Settle Off-label Drug Marketing Charges"
taylor (5/11/2011 at 6:01 AM)

There's a lot of discussion about the state of medical care in the United States The doctor-patient partnership is heavily emphasized, for instance. For a while now, there has been a somewhat muffled undercurrent of doctors taking pharmaceutical business kickbacks to prescribe only certain medications to patients, and not always in the best interest of the patient. Accusations abound that the medical industry is rife with corruption. Taking out an <a title="Apply here for an installment loan" href="">installment loan</a> for prescription is probably not the best thing for you after-all.


FREE e-Newsletters Join the Council Subscribe to HL magazine


100 Winners Circle Suite 300
Brentwood, TN 37027


About | Advertise | Terms of Use | Privacy Policy | Reprints/Permissions | Contact
© HealthLeaders Media 2015 a division of BLR All rights reserved.